Machahua Carlos, Marti Thomas M, Dorn Patrick, Funke-Chambour Manuela
Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Lung Precision Medicine (LPM), Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
Respir Res. 2025 Jan 28;26(1):44. doi: 10.1186/s12931-025-03110-2.
Fibrotic cocktail (FC) is a combination of pro-fibrotic and pro-inflammatory mediators that induces early fibrotic changes in organotypic lung models. We hypothesised that transforming growth factor beta 1 (TGF-β1) alone induces a pro-fibrotic effect similar to FC. Our aim was to compare the pro-fibrotic effects of TGF-β1 with FC in human precision-cut lung slices (PCLS).
PCLS from "healthy" lung tissue of cancer patients undergoing surgery (n = 7) were incubated with TGF-β1, FC or control for 72 h. Gene expression markers for myofibroblasts differentiation, extracellular matrix (ECM), as well as TGF-β receptors were assessed (RT-qPCR). ECM proteins expression in lysates and supernatant was assessed by ELISA and immunofluorescence.
We found that TGF-β1 significantly increased gene expression of ACTA2, COL1A1, CCN2, and VIM compared to control but also compared to FC. FC showed a significant increase of matrix metalloproteinase (MMP) 7 and 1 compared to control, while TGF-β receptor 2 was lower after FC compared to TGF-β1 or control. FC or TGF-β1 showed similar fibronectin protein expression in lysates and supernatants, while type I collagen protein expression in lysates was significantly greater with TGF-β1 compared to control.
Our findings show that TGF-β1 induces consistent pro-fibrotic changes in PCLS after 72 h. Compared to TGF-β1, FC treatment resulted in reduced gene expression of TGF-β receptor 2 and increased MMPs expression, potentially mitigating the early pro-fibrotic effects. Selecting specific pro-fibrotic stimuli may be preferable depending on the research question and time point of interest in lung fibrosis studies using PCLS.
纤维化混合物(FC)是促纤维化和促炎介质的组合,可在器官型肺模型中诱导早期纤维化变化。我们假设单独的转化生长因子β1(TGF-β1)会诱导出与FC相似的促纤维化作用。我们的目的是比较TGF-β1与FC在人精密切割肺切片(PCLS)中的促纤维化作用。
将来自接受手术的癌症患者“健康”肺组织的PCLS(n = 7)与TGF-β1、FC或对照孵育72小时。评估肌成纤维细胞分化、细胞外基质(ECM)以及TGF-β受体的基因表达标志物(RT-qPCR)。通过ELISA和免疫荧光评估裂解物和上清液中ECM蛋白的表达。
我们发现,与对照相比,TGF-β1显著增加了ACTA2、COL1A1、CCN2和VIM的基因表达,与FC相比也是如此。与对照相比,FC显示基质金属蛋白酶(MMP)7和1显著增加,而与TGF-β1或对照相比,FC处理后TGF-β受体2较低。FC或TGF-β1在裂解物和上清液中显示出相似的纤连蛋白蛋白表达,而与对照相比,TGF-β1处理后裂解物中I型胶原蛋白蛋白表达显著更高。
我们的研究结果表明,TGF-β1在72小时后可在PCLS中诱导一致的促纤维化变化。与TGF-β1相比,FC处理导致TGF-β受体2的基因表达降低,MMPs表达增加,可能减轻早期促纤维化作用。根据使用PCLS的肺纤维化研究中的研究问题和感兴趣的时间点,选择特定的促纤维化刺激可能更可取。